Patents by Inventor Sanjib Bera

Sanjib Bera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250186591
    Abstract: Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: February 13, 2025
    Publication date: June 12, 2025
    Inventors: Sanjib BERA, Sven GUENTHER, Adam SMITH, Travis MICKLE
  • Patent number: 12251445
    Abstract: Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: March 18, 2025
    Inventors: Sanjib Bera, Sven Guenther, Adam Smith, Travis Mickle
  • Publication number: 20250032479
    Abstract: The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((-)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Application
    Filed: July 29, 2024
    Publication date: January 30, 2025
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20240317688
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of levorphanol.
    Type: Application
    Filed: May 6, 2024
    Publication date: September 26, 2024
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 12076316
    Abstract: The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((?)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: September 3, 2024
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 12012384
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: June 18, 2024
    Assignee: ZEVRA THERAPEUTICS, INC.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20230382851
    Abstract: Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 30, 2023
    Inventors: Sanjib BERA, Dibyendu DANA, Sven GUENTHER, Adam SMITH, Travis MICKLE
  • Publication number: 20230382881
    Abstract: Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 30, 2023
    Inventors: Sanjib BERA, Dibyendu DANA, Sven GUENTHER, Adam SMITH, Travis MICKLE
  • Publication number: 20230382880
    Abstract: Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 30, 2023
    Inventors: Sanjib BERA, Sven GUENTHER, Adam SMITH, Travis MICKLE
  • Publication number: 20230338543
    Abstract: Disclosed are compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions.
    Type: Application
    Filed: April 19, 2023
    Publication date: October 26, 2023
    Inventors: Sanjib BERA, Dibyendu DANA, Sven GUENTHER, Adam SMITH, Travis MICKLE
  • Publication number: 20220096463
    Abstract: The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((?)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20220089544
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.
    Type: Application
    Filed: November 29, 2021
    Publication date: March 24, 2022
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 11234975
    Abstract: The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((?)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 1, 2022
    Assignee: KEMPHARM, INC.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 11214544
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: January 4, 2022
    Assignee: KEMPHARM, INC.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20210002226
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to levorphanol ((?)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Application
    Filed: April 12, 2018
    Publication date: January 7, 2021
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20200390757
    Abstract: The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((?)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 17, 2020
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20200392087
    Abstract: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 17, 2020
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 10758528
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 1, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Publication number: 20200030316
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 30, 2020
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10544153
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 28, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin